<h2 data-section-id="l8pw86" data-start="0" data-end="34"><strong>Neuroendocrine Carcinoma Market</strong></h2>
<p data-start="36" data-end="695">The <a href="https://www.delveinsight.com/report-store/neuroendocrine-carcinoma-market"><strong>Neuroendocrine Carcinoma (NEC) market</strong></a> is anticipated to witness substantial growth across the 7MM during the forecast period from 2026-2036, primarily driven by rising disease incidence, improved diagnostic capabilities, and the emergence of targeted immunotherapies. The market size in the 7MM was estimated at nearly USD 30 million in 2025, while a CAGR of 15.2% is projected through 2036. Increasing adoption of biomarker-driven oncology approaches and advancements in molecular profiling are further strengthening market expansion. Moreover, pharmaceutical companies are actively investing in innovative <a href="https://www.delveinsight.com/report-store/delta-like-ligand-3-targeted-therapies-market-forecast"><strong>DLL3-targeted therapies</strong></a> for extrapulmonary NEC.</p>
<h3 data-start="697" data-end="720"><strong data-start="697" data-end="720">Key Market Insights</strong></h3>
<ul data-start="721" data-end="1069">
<li data-section-id="z4ipty" data-start="721" data-end="771">7MM market size in 2025: nearly USD 30 million</li>
<li data-section-id="19z37f9" data-start="772" data-end="808">Expected CAGR (2026-2036): 15.2%</li>
<li data-section-id="1ge5cxj" data-start="809" data-end="873">Rising focus on precision oncology and targeted therapeutics</li>
<li data-section-id="ardfb0" data-start="874" data-end="952">Obrixtamig (BI 764532) is expected to generate the highest revenue by 2036</li>
<li data-section-id="18d49lx" data-start="953" data-end="1069">Growing utilization of advanced imaging and pathology services supports earlier detection and treatment planning</li>
</ul>
<h2 data-section-id="1klg0nd" data-start="1076" data-end="1116"><strong>Neuroendocrine Carcinoma Epidemiology</strong></h2>
<p data-start="1118" data-end="1740"><a href="https://www.delveinsight.com/report-store/neuroendocrine-carcinoma-epidemiology-forecast"><strong>Neuroendocrine Carcinoma</strong></a> represents a rare yet highly aggressive malignancy with a considerable disease burden across the 7MM. In 2025, the total incident cases of Neuroendocrine Neoplasms (NENs) in the 7MM were estimated at nearly 20,000, while extrapulmonary NEC accounted for approximately 1,900 incident cases. The United States represented the largest patient share with nearly 48% of cases, followed by the EU4 and the UK at 31%, and Japan at 21%. Improved awareness, enhanced imaging technologies, and specialized pathology services are contributing to better identification and staging of NEC across major markets.</p>
<h3 data-start="1742" data-end="1769"><strong data-start="1742" data-end="1769">Epidemiology Highlights</strong></h3>
<ul data-start="1770" data-end="2155">
<li data-section-id="140i75r" data-start="1770" data-end="1811">Total incident cases in the 7MM: ~20K</li>
<li data-section-id="nfefwt" data-start="1812" data-end="1856">Extrapulmonary NEC incident cases: ~1.9K</li>
<li data-section-id="pckgyl" data-start="1857" data-end="1903">US accounted for nearly 48% of total cases</li>
<li data-section-id="tqpca5" data-start="1904" data-end="1952">EU4 and the UK contributed approximately 31%</li>
<li data-section-id="w8swh6" data-start="1953" data-end="1994">Japan represented around 21% of cases</li>
<li data-section-id="7hmsoj" data-start="1995" data-end="2071">Stage IV disease accounted for nearly 34% of cases in the EU4 and the UK</li>
<li data-section-id="spev3w" data-start="2072" data-end="2155">Japan reported nearly 7,000 NEN cases and approximately 4,000 NEC cases in 2025</li>
</ul>
<h2 data-section-id="14cj7ts" data-start="2162" data-end="2198"><strong>Neuroendocrine Carcinoma Pipeline</strong></h2>
<p data-start="2200" data-end="2902">The Neuroendocrine Carcinoma pipeline is gradually evolving with the development of novel immunotherapies and DLL3-targeted agents aimed at improving outcomes in this highly aggressive cancer. Currently, there are no specifically approved marketed drugs for NEC, and treatment mainly depends on platinum-based chemotherapy combinations such as cisplatin or carboplatin with etoposide. Emerging therapies are primarily focused on DLL3-directed mechanisms, including bispecific antibodies and antibody-drug conjugates (ADCs). Several biotechnology and pharmaceutical companies are actively advancing innovative candidates that may significantly transform the NEC treatment landscape over the next decade.</p>
<h3 data-start="2904" data-end="2922"><strong data-start="2904" data-end="2922">Emerging Drugs</strong></h3>
<ul data-start="2923" data-end="3460">
<li data-section-id="1tbbwh1" data-start="2923" data-end="3069"><strong data-start="2925" data-end="2951">Obrixtamig (BI 764532)</strong> - DLL3 &times; CD3 bispecific antibody by <span class="whitespace-normal">Boehringer Ingelheim</span> and <span class="whitespace-normal">Oxford BioTherapeutics</span></li>
<li data-section-id="101c51u" data-start="3070" data-end="3174"><strong data-start="3072" data-end="3098">Tarlatamab (IMDELLTRA)</strong> - DLL3 &times; CD3 bispecific antibody by <span class="whitespace-normal">Amgen</span></li>
<li data-section-id="dmpkfo" data-start="3175" data-end="3318"><strong data-start="3177" data-end="3213">Zocilurtatug pelitecan (ZL-1310)</strong> - DLL3-targeted ADC by <span class="whitespace-normal">Zai Lab</span> and <span class="whitespace-normal">MediLink Therapeutics</span></li>
<li data-section-id="pe773o" data-start="3319" data-end="3460"><strong data-start="3321" data-end="3344">Gocatamig (MK-6070)</strong> - DLL3-targeted T-cell engager by <span class="whitespace-normal">Merck &amp; Co.</span> and <span class="whitespace-normal">Daiichi Sankyo</span></li>
</ul>
<h3 data-start="3462" data-end="3481"><strong data-start="3462" data-end="3481">Key Unmet Needs</strong></h3>
<ul data-start="3482" data-end="3657" data-is-last-node="" data-is-only-node="">
<li data-section-id="146eowk" data-start="3482" data-end="3515">Delayed and complex diagnosis</li>
<li data-section-id="581f7c" data-start="3516" data-end="3567">Limited effectiveness of conventional therapies</li>
<li data-section-id="7jbq2i" data-start="3568" data-end="3607">Lack of approved targeted therapies</li>
<li data-section-id="1so60bh" data-start="3608" data-end="3657" data-is-last-node="">Rapid metastatic progression and poor prognosis</li>
</ul>

Neuroendocrine Carcinoma Market

Neuroendocrine Carcinoma Market Infographic

Neuroendocrine Carcinoma Market Thumbnail

Neuroendocrine Carcinoma Market Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape